Diffuse large B-cell lymphoma and Burkitt lymphoma

2008 Arima, 2013, The impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma, Leuk Lymphoma, 54, 2645, 10.3109/10428194.2013.788697 Ott, 2010, Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL, Blood, 116, 4916, 10.1182/blood-2010-03-276766 Jain, 2013, Recent advances in de novo CD5+ diffuse large B cell lymphoma, Am J Hematol, 88, 798, 10.1002/ajh.23467 Rodriguez-Justo, 2008, Cyclin D1-positive diffuse large B-cell lymphoma, Histopathology, 52, 900, 10.1111/j.1365-2559.2008.03042.x Barrans, 2004, Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome, Blood, 104, 2933, 10.1182/blood-2004-03-1209 Rosenwald, 2002, The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, N Engl J Med, 346, 1937, 10.1056/NEJMoa012914 Hans, 2004, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, 103, 275, 10.1182/blood-2003-05-1545 Choi, 2009, A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy, Clin Cancer Res, 15, 5494, 10.1158/1078-0432.CCR-09-0113 Coutinho, 2013, Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies, Clin Cancer Res, 19, 6686, 10.1158/1078-0432.CCR-13-1482 Horn, 2013, MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma, Blood, 121, 2253, 10.1182/blood-2012-06-435842 Pfreundschuch, 2012, Growing importance of MYC/BLC2 immunohistochemistry in DLBCL, J Clin Oncol, 30, 3433, 10.1200/JCO.2012.44.4729 Pasqualucci, 2011, Analysis of the coding genome of diffuse large B-cell lymphoma, Nat Genet, 43, 830, 10.1038/ng.892 Alizadeh, 2011, Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment, Blood, 118, 1350, 10.1182/blood-2011-03-345272 Iqbal, 2015, Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma, Blood, 125, 1137, 10.1182/blood-2014-04-566778 2011, J Clin Oncol, 29 Van Loo, 2009, T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response, Haematologica, 95, 440, 10.3324/haematol.2009.009647 Fan, 2003, Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation, Am J Surg Pathol, 27, 1346, 10.1097/00000478-200310000-00007 Senff, 2007, Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers, J Clin Oncol, 25, 1581, 10.1200/JCO.2006.09.6396 Oyama, 2007, Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients, Clin Cancer Res, 13, 5124, 10.1158/1078-0432.CCR-06-2823 Petrich, 2014, Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis, Blood, 124, 2354, 10.1182/blood-2014-05-578963 Perry, 2014, MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab, Br J Haematol, 165, 382, 10.1111/bjh.12763 Gualco, 2012, The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases, Mod Pathol, 25, 661, 10.1038/modpathol.2011.200 Rodig, 2010, The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying C-MYC translocated lymphomas, Haematologica, 95, 2056, 10.3324/haematol.2010.025767 Schlee, 2007, C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma, Int J Cancer, 120, 1387, 10.1002/ijc.22372